Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Piper Jaffray Lowers Mankind to Market Perform


Piper Jaffray downgraded Mankind (MNKD) to market perform from outperform.

Analyst Thomas Wei says recent litigation may weigh on Mankind stock, so he downgrades. He notes that in an 8-K filing last week, Mankind disclosed recently initiated litigation between the company and its departed chief medical officer, Wendell Cheatham.

Wei notes Dr. Cheatham claimed wrongful termination and raised allegations of false statements made by the company in a March letter to the FDA, which requested a meeting with the FDA to discuss the manufacturing process for Technosphere Insulin.

In the wake of uncertainty on timelines, manufacturing allegations, and pending litigation, he lowers his $20 target price to $13.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus